Prurigo Clinical Trial
Official title:
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis
The purpose of this study is to evaluate the safety and tolerability of Ruxolitinib cream in participants with Prurigo Nodularis (PN).
The study comprises of a 12 week double-blind, vehicle-controlled (DBVC) treatment period, followed by a 40 week open label extension period, and 30 day safety follow-up period During the double blind period, all PN-affected areas identified at baseline will be treated, and during the open label period, only active PN-affected areas will be treated. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03340155 -
Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases
|
N/A | |
| Completed |
NCT02174419 -
Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis
|
Phase 2/Phase 3 | |
| Completed |
NCT02174432 -
Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis
|
Phase 2/Phase 3 |